Flosequinan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Flosequinan
Accession Number
DB13228
Type
Small Molecule
Groups
Approved
Description

Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials 1.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
6NB119DLU7
CAS number
76568-02-0
Weight
Average: 239.26
Monoisotopic: 239.041627903
Chemical Formula
C11H10FNO2S
InChI Key
UYGONJYYUKVHDD-UHFFFAOYSA-N
InChI
InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3
IUPAC Name
7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one
SMILES
CN1C=C(C(=O)C2=C1C=C(F)C=C2)S(C)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Patent BlueThe therapeutic efficacy of Flosequinan can be decreased when used in combination with Patent Blue.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Packer M, Pitt B, Rouleau JL, Swedberg K, DeMets DL, Fisher L: Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. JACC Heart Fail. 2017 Jun;5(6):399-407. doi: 10.1016/j.jchf.2017.03.003. Epub 2017 May 10. [PubMed:28501522]
External Links
ChemSpider
3672315
ChEBI
134972
ChEMBL
CHEMBL1908307
Wikipedia
Flosequinan
ATC Codes
C01DB01 — Flosequinan

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.25 mg/mLALOGPS
logP1.13ALOGPS
logP0.72ChemAxon
logS-1.5ALOGPS
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity63.82 m3·mol-1ChemAxon
Polarizability22.88 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinolones and derivatives
Direct Parent
Hydroquinolones
Alternative Parents
Haloquinolines / Hydroquinolines / Aryl fluorides / Benzenoids / Pyridines and derivatives / Vinylogous amides / Heteroaromatic compounds / Sulfoxides / Azacyclic compounds / Sulfinyl compounds
show 6 more
Substituents
Haloquinoline / Dihydroquinolone / Dihydroquinoline / Aryl fluoride / Aryl halide / Pyridine / Benzenoid / Heteroaromatic compound / Vinylogous amide / Sulfoxide
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on September 02, 2019 19:54